New drug combo shows promise against tough leukemia

NCT ID NCT03330821

First seen Nov 16, 2025 · Last updated May 12, 2026 · Updated 27 times

Summary

This study tests a new drug called pevonedistat alongside standard chemotherapy (cytarabine and idarubicin) in people newly diagnosed with high-risk acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination improves the chance of complete remission. About 53 adults will participate, and the focus is on controlling the disease rather than curing it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Los Angeles County-USC Medical Center

    Los Angeles, California, 90033, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Arizona Cancer Center - North Campus

    Tucson, Arizona, 85724, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.